Abstract: The present invention provides immunogenic compositions comprising peptides derived from the amino acid sequence of P. aeruginosa for protecting susceptible hosts against diseases caused by bacterial pathogens which secrete a zinc metalloprotease.

Abstract: The present invention relates to parasitic helminth proteins of about 39 kD (i.e., P39 proteins); to parasitic helminth P39 nucleic acid molecules, including those that encode such proteins; and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, and/or antibodies as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.

Abstract: The present invention relates to parasitic helminth PLA2 proteins; to parasitic helminth PLA2 nucleic acid molecules, including those that encode such proteins; to antibodies raised against such proteins; and to compounds that inhibit parasitic helminth phospholipase A.sub.2 activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitors. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies, and/or inhibitors as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.

Abstract: Vaccines for diseases caused by normally encapsulated organisms are produced by genetically modifying those organisms by deleting the genes encoding for capsule synthesis or a portion thereof sufficient to produce non-capsulated mutants of the organisms. As an example, a live, attenuated strain of Actinobacillus pleuropneumoniae genetically modified with a large deletion in a chromosomal regions of the DNA which encodes for capsule synthesis is a safe and effective vaccine against swine pleuropneumonia.

Abstract: A novel signal amplification system for immunoassays that minimizes non-specific signals is disclosed. Immunoassay methods, reagents and test kits are described for obtaining immunoassays of enhanced sensitivity. The reagents include antibody-variant DNA conjugates, wherein the variant DNA is a substrate for an RNA-dependent RNA polymerase, such as, QB replicase. Immunoassay methods to detect, or to detect and quantitate, analyte in test samples comprise transcribing the variant DNA of said antibody-DNA conjugates that are bound to analyte, to RNA, and replicating the RNA transcripts, wherein the presence or quantity of variant RNA replication products can be correlated with the presence or quantity of analyte in the test samples. Further, methods are provided to detect, or to detect and quantitate, simultaneously two or more analytes in a test sample.

Abstract: The present invention provides nucleic acid molecules containing nucleotide sequences encoding helminth aminopeptidase enzymes, and antigenic fragments and functionally-equivalent variants thereof, their use in the preparation of vaccines for use against helminth parasites, and synthetic polypeptides encoded by them.

Abstract: The present invention relates to parasitic helminth PLA2 proteins; to parasitic helminth PLA2 nucleic acid molecules, including those that encode such proteins; to antibodies raised against such proteins; and to compounds that inhibit parasitic helminth phospholipase A.sub.2 activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitors. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies, and/or inhibitors as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.

Abstract: This application discloses SPE-4 related peptides, peptide-carrier protein conjugates and fusion proteins, immunogenic compositions, antibodies and methods for characterizing the SPE-4 related protein profiles, useful in diagnosing or monitoring SPE-4 related protein profiles of nematodes and/or Alzheimer's disease patients, either in postmortem tissue, preferably from the frontal cortex of the brain, or from other tissue samples, including without limitation muscles and peripheral blood or in a tissue samples of a living patient, where the tissue analyzed can includes brain, muscle or peripheral blood cells.

Abstract: A method of treating vegetation by application of a microbial insecticide in which a quinone has been covalently bonded to the viral occlusion body surface of the microbial insecticide in order to improve the UV stability of the microbial insecticide by forming a protective shield around the pathogen.

Abstract: The invention relates to certain stable vaccine compositions comprising a macrocyclic lactone compound, a milbemycin compound, an avermectin compound or mixtures thereof; at least one antigen; a dispersing agent; an adjuvant; a water soluble organic solvent; and saline or water or mixtures thereof. The invention further relates to stable compositions as described above of a macrocyclic lactone compound, a milbemycin compound, an avermectin compound or mixtures thereof, but without an antigen. The invention also relates to a method for preventing or controlling helminthiasis, infection by acarids and arthropod endo-and ectoparasites and bacterial and viral disease in warm-blooded animals by the parenteral administration of compositions of the invention. The invention further relates to a process for the preparation of the invention compositions.

Abstract: Disclosed is a 12-kDa PPD protein isolated and purified from the purified protein derivative, the major fraction of Mycobacterium tuberculosis that protects mice against the induction of experimental autoimmune encephalomyelitis (EAE), and salts, functional derivatives, analogs and active fractions thereof, and pharmaceutical compositions comprising them for the treatment of autoimmune diseases.

Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.

Abstract: The present invention relates to parasitic helminth proteins of about 39 kD (i.e., P39 proteins); to parasitic helminth P39 nucleic acid molecules, including those that encode such proteins; and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, and/or antibodies as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.

Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.

Abstract: A label-based assay is described, through modifications of substrate strure and derivatization of serum albumin, which can be used to determine type A proteolytic activity without separation of products.

Abstract: A process for the removal of catalyst poisons from hops and hop extracts is disclosed. After processing the hops to extract the alpha or beta acids therein, the alpha or beta acids are treated with activated nickel catalyst. The activated nickel catalyst binds the catalyst poisons which are believed to be sulfur containing compounds. The activated nickel and catalyst poisons are separated from the alpha or beta acids, and the alpha or beta acids are then hydrogenated and isomerized into tetrahydroisoalpha acids.

Abstract: The present invention provides a human glutamate-binding protein (HGLUBP) and polynucleotides which identify and encode HGLUBP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGLUBP and a method for producing HGLUBP. The invention also provides for use of HGLUBP and agonists, antibodies, or antagonists specifically binding HGLUBP, in the prevention and treatment of diseases associated with expression of HGLUBP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGLUBP for the treatment of diseases associated with the expression of HGLUBP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGLUBP.

Abstract: A vaccine comprising purified outer-polysaccharide (OPS) is effective for protection against brucellosis. The vaccine is derived from Brucella or a variety of cross reactive bacteria. The vaccine can be administered by different routes (intramuscularly, subcutaneously, intraperitoneally, orally). The vaccine is effective in protecting against other infectious bacteria, aside from Brucella. It is likely that the vaccine can be given after infection to reduce illness.

Abstract: Receptors for the zonula occludens toxin of Vibrio cholera, as well as methods involving the use of the same are disclosed.

Abstract: A method and vaccine for treatment of pythiosis in humans and animals is described. In particular a vaccine comprising a mixture of extracellular and intracellular proteins is described. The vaccine enables cures of chronic pythiosis in some patients.